Northern Trust Corp Gemini Therapeutics, Inc. Transaction History

Northern Trust Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.22 - $1.73 $178,967 - $253,782	-146,695 Reduced 75.1%	48,645 $82,000
Q1 2022 May 13, 2022	SELL	$1.29 - $3.08 $7,305 - $17,442	-5,663 Reduced 2.82%	195,340 $272,000
Q4 2021 Feb 08, 2022	SELL	$2.39 - $4.0 $10,915 - $18,268	-4,567 Reduced 2.22%	201,003 $585,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $56,588 - $108,375	-17,148 Reduced 7.7%	205,570 $830,000
Q2 2021 Aug 13, 2021	BUY	$6.32 - $14.02 $1.05 Million - $2.32 Million	165,510 Added 289.31%	222,718 $1.44 Million
Q1 2021 May 12, 2021	BUY	$11.32 - $18.0 $647,594 - $1.03 Million	57,208 New	57,208 $775,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.